June 26, 2024 06:30 AM Eastern Daylight Time
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
View Full Size
Download
Full Size
JPEG, 1226x191, 82.9 KB
Small
JPEG, 480x75, 35.5 KB
Preview
JPEG, 144x22, 6.9 KB
Thumbnail
JPEG, 120x19, 5.8 KB
Smart Multimedia Gallery
Share
Facebook
Twitter
LinkedIn
Delicious
Reddit
StumbleUpon
Digg
MySpace
Newsvine
Google Bookmark
Yahoo! Bookmark
Email
All News
|
News with Multimedia
>
Press Release: Savara Announces Molgramostim Nebulizer Solutio...
Get Business Wire News on Your Website
Terms of Use
|
© 2024 Business Wire